efungumab

Efungumab is a single-chain variable fragment of a human monoclonal antibody developed as an antifungal agent. It specifically targets fungal heat shock protein 90 (Hsp90), inhibiting its function and thereby interfering with fungal viability. Efungumab was primarily investigated for the treatment of invasive candidiasis and candidemia, often in combination with amphotericin B or other antifungal agents. The drug demonstrated synergistic effects with standard antifungals in preclinical studies and early clinical trials. However, its development was discontinued after regulatory authorities raised concerns about product safety and quality[1][4][5][7]. Efungumab was originally developed by NeuTec Pharma, which became a subsidiary of Novartis.

Brand names

Mycograb

Other names

Immunoglobulin, anti-(candida heat-shock protein hsp 90) (human monoclonal hsp90mab fragment)